Nafazolin

Nafazolin
(IUPAC) ime
	2-(naftalen-1-ilmetil)-4,5-dihidro-1H-imidazol
Klinički podaci
Robne marke	Naphcon-a
AHFS/Drugs.com	Monografija
Identifikatori
CAS broj	835-31-4
ATC kod	R01AA08
PubChem	4436
DrugBank	DB06711
ChemSpider	4283
UNII	H231GF11BV
KEGG	D08253
ChEMBL	CHEMBL761
Hemijski podaci
Formula	C14H14N2
Mol. masa	210,274
SMILES	eMolekuli & PubHem
InChI
	InChI=1S/C14H14N2/c1-2-7-13-11(4-1)5-3-6-12(13)10-14-15-8-9-16-14/h1-7H,8-10H2,(H,15,16) ; Key: CNIIGCLFLJGOGP-UHFFFAOYSA-N
Farmakoinformacioni podaci
Trudnoća	?
Pravni status
Način primene	Topikalno

Nafazolin (2-(1-naftilmetil)-2-imidazolin hidrohlorid) je simpatomimetički lek sa znatnom alfa adrenergičkom aktivnošću. On je vazokonstriktor sa brzim dejstvom u redukovanju otoka kad se primeni na sluzokožu. On deluje na alfa receptore u arteriolama konjunktiva i proizvodi konstrikciju, i to dovodi do umanjene kongestije. On je aktivni sastojak u nekoliko formulacija koje su u prodaji na slobodno, uključujući Clear Eyes i Nafkon kapi za oči.^[6]

Hemija

Nafazolin se sintetiše iz (1-nafthil)acetonitrila, koji se nakon reakcije sa etanolom transformiše u iminoestar, i podleže daljoj heterociklizaciji u željeni imidazolinski derivat nakon reakcije sa etilendiaminom.^[7]

Reference

↑ Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit
↑ Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.
↑ Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit
↑ Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.
↑ Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit
↑ „Ophthalmology: naphazoline”. Tarascon Pocket Pharmacopoeia 2009. Jones and Bartlett Publishers. 2008. ISBN 0-7637-6572-4.
↑ A. Sonn, U.S. Patent 2.161.938 (1939)

Spoljašnje veze

	Portal Medicina
	Portal Hemija

[1] Li Q, Cheng T, Wang Y, Bryant SH (2010). „PubChem as a public resource for drug discovery.”. Drug Discov Today 15 (23-24): 1052-7. DOI:10.1016/j.drudis.2010.10.003. PMID 20970519. edit

[2] Evan E. Bolton, Yanli Wang, Paul A. Thiessen, Stephen H. Bryant (2008). „Chapter 12 PubChem: Integrated Platform of Small Molecules and Biological Activities”. Annual Reports in Computational Chemistry 4: 217-241. DOI:10.1016/S1574-1400(08)00012-1.

[3] Hettne KM, Williams AJ, van Mulligen EM, Kleinjans J, Tkachenko V, Kors JA. (2010). „Automatic vs. manual curation of a multi-source chemical dictionary: the impact on text mining”. J Cheminform 2 (1): 3. DOI:10.1186/1758-2946-2-3. PMID 20331846. edit

[4] Joanne Wixon, Douglas Kell (2000). „Website Review: The Kyoto Encyclopedia of Genes and Genomes — KEGG”. Yeast 17 (1): 48–55. DOI:10.1002/(SICI)1097-0061(200004)17:1<48::AID-YEA2>3.0.CO;2-H.

[5] Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. (2012). „ChEMBL: a large-scale bioactivity database for drug discovery”. Nucleic Acids Res 40 (Database issue): D1100-7. DOI:10.1093/nar/gkr777. PMID 21948594. edit

[6] „Ophthalmology: naphazoline”. Tarascon Pocket Pharmacopoeia 2009. Jones and Bartlett Publishers. 2008. ISBN 0-7637-6572-4.

[7] A. Sonn, U.S. Patent 2.161.938 (1939)

[1]

[2]

[3]

[4]

[5]

[6]

[7]